title: What we have learned from the Xaliproden Sanofi-aventis trials.
authors.affiliation: Sanofi-aventis, Montpellier, France.
authors.forename: P
authors.initials: P
authors.lastname: Douillet
authors.forename: J M
authors.initials: JM
authors.lastname: Orgogozo
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology; D015415:Biomarkers; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009281:Naphthalenes / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design
chemical_list: D015415:Biomarkers; D009281:Naphthalenes; D011725:Pyridines; C462299:xaliproden